HUADONG MEDICINE(SZ:000963) Zheng Quan Zhi Xing·2025-06-30 16:45Core Viewpoint - The report discusses the independent financial advisory opinion regarding the restricted stock incentive plan of East China Pharmaceutical Co., Ltd., focusing on the fairness and reasonableness of the plan for shareholders and its impact on the company's sustainable operation [2][3]. Group 1: Incentive Plan Overview - The restricted stock incentive plan was approved through necessary procedures, including independent directors' opinions on its benefits for the company's sustainable development [4][5]. - The plan involves granting restricted stocks to directors, senior management, middle management, and core technical personnel, with specific conditions for vesting and transfer restrictions [1][2]. Group 2: Stock Repurchase and Cancellation - The company plans to repurchase and cancel 5.60 thousand shares of restricted stock due to the departure of six individuals who no longer qualify for the incentive [13][14]. - The repurchase represents 1.21% of the total restricted stocks granted under the incentive plan and 0.003% of the company's total share capital before the repurchase [14]. - The adjusted repurchase price for the restricted stocks is set at 23.20 yuan per share, following the company's profit distribution plan [14]. Group 3: Approval and Compliance - The independent financial advisor confirms that the adjustments to the repurchase price and the cancellation of restricted stocks have obtained necessary approvals and comply with relevant laws and regulations [13][14]. - The company must still fulfill the shareholder meeting review process and disclose relevant information as per regulations [14].